07:45 AM EDT, 07/10/2025 (MT Newswires) -- Biogen (BIIB) and Stoke Therapeutics ( STOK ) said Thursday that data from an analysis evaluating the potential effects of the phase 3 zorevunersen dosing regimen to treat the underlying cause of Dravet syndrome showed improvements in cognition and behavior at week 68.

The data were complementary to that previously reported from a broader cohort of patients treated with zorevunersen in phase 1/2a and open label extension studies showing improvements within the first 9 months, continuing through an additional two years, the companies said.

The new analysis is best aligned with the timing and dosing regimen that will be evaluated in the pivotal phase 3 EMPEROR study, the companies said.